RELISTOR (methylnaltrexone bromide) - Important Safety Information from Wyeth as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 27/09/2010

 

Problem Or Issue:
Important safety information communication from Wyeth on new information regarding RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection. Post marketing cases of gastrointestinal (GI) perforation have been reported in patients receiving Relistor.

RELISTOR (methylnaltrexone bromide) - Important Safety Information


« Back